The majority of newly generated pre-B cells in the bone marrow are eliminated at the pre-B cell receptor (pre-BCR) checkpoint 1 . Critical survival and proliferation signals come from the pre-BCR; if pre-B cell clones fail to express a functional pre-BCR, then signaling output is too weak. If the pre-BCR binds to ubiquitous self-antigen (autoreactive immunoglobulin µ heavy chain; µ-HC), then pre-BCR signals are strong. Both attenuation below a minimum (such as a nonfunctional pre-BCR) and hyperactivation above a maximum (such as an autoreactive pre-BCR) threshold of signaling strength trigger negative selection and cell death. Approximately 75% of newly generated pre-B cells express an autoreactive µ-HC 2,3 , highlighting the importance of stringent negative selection of autoreactive clones at the pre-BCR checkpoint. Although autoreactive pre-B cell clones are eliminated owing to the toxicity of strong pre-BCR signaling 1-3 , sustained activation of PI3K-AKT signaling is sufficient to rescue B cell survival in the absence of a functional BCR 4 and is required for pre-B cell survival 5 . Likewise, germline mutations in humans that result in either loss or hyperactivation of PI3K-AKT signaling have equally deleterious effects on human early B cell development 6 , suggesting that early B cells undergo selection for an intermediate level of PI3K signaling.
The majority of newly generated pre-B cells in the bone marrow are eliminated at the pre-B cell receptor (pre-BCR) checkpoint 1 . Critical survival and proliferation signals come from the pre-BCR; if pre-B cell clones fail to express a functional pre-BCR, then signaling output is too weak. If the pre-BCR binds to ubiquitous self-antigen (autoreactive immunoglobulin µ heavy chain; µ-HC), then pre-BCR signals are strong. Both attenuation below a minimum (such as a nonfunctional pre-BCR) and hyperactivation above a maximum (such as an autoreactive pre-BCR) threshold of signaling strength trigger negative selection and cell death. Approximately 75% of newly generated pre-B cells express an autoreactive µ-HC 2, 3 , highlighting the importance of stringent negative selection of autoreactive clones at the pre-BCR checkpoint. Although autoreactive pre-B cell clones are eliminated owing to the toxicity of strong pre-BCR signaling [1] [2] [3] , sustained activation of PI3K-AKT signaling is sufficient to rescue B cell survival in the absence of a functional BCR 4 and is required for pre-B cell survival 5 . Likewise, germline mutations in humans that result in either loss or hyperactivation of PI3K-AKT signaling have equally deleterious effects on human early B cell development 6 , suggesting that early B cells undergo selection for an intermediate level of PI3K signaling.
PTEN is a key negative regulator of the PI3K-AKT pathway and functions as a dual protein and lipid phosphatase that dephosphorylates phosphatidylinositol (3, 4, 5) -triphosphate (PIP 3 ). PTEN counteracts the activity of PI3K, which phosphorylates phosphatidylinositol (4,5)-bisphosphate (PIP 2 ) to generate PIP 3 , the membrane anchor and ligand of AKT's pleckstrin homology (PH) domain 7 . Deletions or inactivating mutations of PTEN are frequently observed in all main types of human cancer (on average 8.3% among 37,898 samples studied) 8 . The common outcome of these lesions is increased membrane levels of PIP 3 and AKT hyperactivation. Genetic lesions of PTEN mutations also have a major role in hematopoietic malignancies. For instance, lesions in PTEN and in genes encoding components of the PI3K-AKT pathway are present in up to 50% of T cell lineage ALL cases 9 .
RESULTS

Pten is required for initiation and maintenance of pre-B ALL in vivo
To study a potential role of PTEN and negative regulation of PI3K-AKT signaling, we developed BCR-ABL1-and NRAS G12D -driven mouse models of pre-B ALL (Fig. 1) . To this end, we transformed interleukin (IL)-7-dependent pre-B cells from the bone marrow of mice carrying loxP-flanked (floxed) Pten (Pten fl/fl and Pten +/fl mice) 10 with oncogenic BCR-ABL1 or NRAS G12D . BCR-ABL1 represents the driver oncogene in Philadelphia chromosome-positive (Ph + ) ALL, the most common subtype of pre-B ALL in adults (~30%). RAS pathway lesions affect components encoded by NRAS, KRAS, PTPN11 and NF1, and these occur in ~50% of both adult and pediatric ALL 11 . Together, BCR-ABL1-and NRAS G12D -driven pre-B ALL reflect two major nonoverlapping types of human ALL (~80%). For inducible deletion of Pten, pre-B ALL cells were transduced with a construct expressing a r t i c l e s 3 8 0 VOLUME 22 | NUMBER 4 | APRIL 2016 nature medicine a tamoxifen (Tam)-inducible estrogen receptor empty vector control (ER T2 ) or one expressing Cre (Cre-ER T2 ). After selection of the transduced cells with puromycin, Cre was activated by Tam treatment (1 µmol/liter), which induced excision of the loxP-flanked Pten alleles and depletion of PTEN protein within 2 d (Fig. 1a) . Notably, inducible Cre-mediated deletion of Pten in pre-B ALL cells resulted in the rapid cell death of leukemia cells ( Fig. 1b and Supplementary Fig. 1a ).
To address whether loss of PTEN affected not only survival of established leukemia but also initiation of leukemia, we reversed the order and first induced deletion of Pten in IL7-dependent Pten fl/fl pre-B cells and subsequently induced BCR-ABL1-mediated transformation. Two days after induction of Cre, Pten +/+ and Pten −/− pre-B cells were transduced with a construct encoding green fluorescent protein (GFP)-tagged BCR-ABL1 (BCR-ABL1 GFP ). Pten +/+ pre-B cells showed rapid outgrowth of BCR-ABL1 GFP -expressing clones, indicating leukemic transformation. In contrast, Pten −/− pre-B cells carrying BCR-ABL1 GFP were not susceptible to malignant transformation by BCR-ABL1 ( Fig. 1c and Supplementary Fig. 1b) . These findings were recapitulated in an in vivo transplant setting. BCR-ABL1-transformed Pten fl/fl pre-B ALL cells caused a fatal leukemia in transplant-recipient mice within 18 d. Luciferase bioimaging revealed that Cre-mediated deletion of Pten did not interfere with engraftment of pre-B ALL cells. However, pre-B ALL cells failed to initiate fatal disease in the absence of PTEN, and the transplant recipients survived for indefinite periods of time (Fig. 1d) .
Minimal residual disease (MRD) analysis, using genomic PCR, revealed no trace of covert leukemia clones (Supplementary Fig. 1c ).
Pten mediates feedback regulation of pre-BCR and its co-receptor CD19 To elucidate the mechanism of how the tumor suppressor PTEN, seemingly paradoxically, enables oncogenic transformation of pre-B cells, we studied gene expression changes after inducible Pten deletion (Fig. 1e) . Loss of Pten induced expression of multiple markers of lymphocyte activation including Cd80, Cd86, Il2ra (also known as Cd25) and Ly6a (also known as Sca-1). Pten deletion resulted in downregulation of the IL-7 receptor (IL-7R), both at the mRNA level and in its surface expression (Fig. 1e,f) . In addition, expression of genes encoding multiple components of the pre-BCR (Ighm, Vpreb1 and Syk) and its co-receptor CD19 were all downregulated after deletion of Pten (Fig. 1e,f) . In pre-B cells, PI3K-AKT signaling is initiated from the pre-BCR via SYK 4, 5, 12, 13 and CD19 via recruitment of PI3K 14, 15 to a YXXM motif in the cytoplasmic tail of CD19. For this reason, loss of pre-BCR and CD19 expression in response to deletion of Pten suggests PTEN-mediated feedback regulation of these PI3K-AKT activating receptors. Likewise, a B cell-specific deletion of Pten in Cd79a tm1(cre)Reth ;Pten fl/fl mice caused loss of CD19 expression in B lineage cells (Fig. 1g) . Western blot analysis confirmed near-complete loss of CD19 protein expression after deletion of Pten, as shown by loss of both surface and intracellular expression of CD19 (Fig. 1h) .
Deletion of Pten compromises BCR-ABL1 and NRAS-driven leukemogenesis BCR-ABL1 and NRAS G12D -driven ALL subtypes were dependent on PTEN function to a similar degree, as inducible, Cre-mediated deletion of Pten induced cell death and reduced colony-forming ability (Fig. 2a,b) . Genotyping of colonies revealed that Pten fl/fl pre-B ALL clones that were able to form colonies had retained floxed Pten alleles despite activation of Cre. Hence, these few colonies arose from pre-B ALL clones that had evaded Cre-mediated deletion of Pten (Supplementary Fig. 2 ).
Pten deletion also induced G0-G1 cell cycle arrest and senescence in pre-B ALL cells (Fig. 2c,d) . To assess the effect of acute ablation of Pten in fully established BCR-ABL1 and NRAS G12D -driven pre-B ALL cells in vivo, 100,000 Pten fl/fl pre-B ALL cells carrying tamoxifen-inducible Cre were injected into sublethally irradiated NOD.CB17-Prkdc scid /J (NOD-SCID) recipient female mice for engraftment. Five days after transplantation of Pten fl/fl pre-B ALL cells, leukemia initiation and engraftment was confirmed by using bioluminescence imaging, and Cre was induced by ten consecutive daily injections of tamoxifen. Consistent with in vitro results, Pten deletion caused leukemia regression in vivo (Fig. 2e) and prolonged overall survival in the recipient mice. We conclude that Pten is required for both initiation and maintenance of pre-B ALL in vivo.
Pre-B ALL cells are exempt from genetic lesions of PTEN Given the unexpected sensitivity of pre-B ALL cells to even a moderate dose reduction of Pten, we reassessed the concept of PTEN as a tumor suppressor in human cancer and in leukemias and lymphomas. A reanalysis of genetic lesions of PTEN in human cancer revealed a high frequency of mutations in solid cancer (8.3% in 37,898 samples) and hematological malignancies (8.4% in 2,548 samples) 8 . In addition to point mutations, deletions of PTEN at chromosome 10q23 are frequent in cancer (5.3% in 8,071 samples studied; Fig. 3a) . These findings are in agreement with previous mechanistic studies demonstrating a tumor suppressor role of PTEN in acute myeloid leukemia 16 , chronic myeloid leukemia (CML) 17 , T cell lineage acute lymphoblastic leukemia 9, 18, 19 and mature B cell lymphoma [20] [21] [22] . However, point mutations in PTEN were not detected in any of the 694 pre-B ALL patient samples evaluated. Likewise, no PTEN deletions were found in the 231 pre-B ALL cases studied (Fig. 3a) . Similarly, although oncogenic activation of the PI3K-AKT pathway in leukemia and lymphoma also occurs through activating mutations in genes encoding agonists of the PI3K-AKT pathway, pre-B ALL cases do not harbor such mutations (Supplementary Fig. 3) . Together, these genetic data suggest that PTEN lesions and other mutations that lead to oncogenic activation of the PI3K-AKT pathway are not favorable in pre-B ALL and that PTEN may have a fundamentally different role in pre-B ALL than in other hematopoietic malignancies.
High expression levels of PTEN in patient-derived pre-B ALL cells Consistent with these findings, our analysis of patient-derived samples showed that PTEN promoter regions are hypermethylated in B cell lymphomas (n = 68) but not in pre-B ALL samples (n = 83; 23 revealed higher PTEN protein levels in samples from individuals with pre-B ALL than in those from individuals with T cell lineage ALL or mature B cell lymphoma (Fig. 3c) . We confirmed these findings by western blot analyses, using a panel of sorted normal human CD19 + pre-B cells (n = 3), patientderived pre-B ALL cells (n = 8) and B cell non-Hodgkin's lymphoma samples (n = 4) (Fig. 3d) . The MDACC (1983 -2007 cohort RPPA data set replicated results from previous work 24 that identified high expression levels of PTEN as a predictor of favorable outcome in individuals with T cell lineage ALL (Supplementary Fig. 4) . In contrast, RPPA data for diagnostic samples from individuals with pre-B ALL showed the opposite trend, with greater-than-median expression levels of PTEN in diagnostic pre-B ALL samples being predictive of shorter relapse-free survival times (Supplementary Fig. 4 ). Pten regulates AKT activity downstream of the pre-B cell receptor To elucidate the mechanistic basis of Pten dependency in pre-B ALL, we first tested the hypothesis that loss of Pten results in hyperactivation of PI3K-AKT signaling and subsequent cell death. In agreement with this hypothesis, we found that inducible deletion of Pten in both BCR-ABL1-and NRAS G12D -driven pre-B ALL cells resulted in increased phosphorylation of AKT at both Ser473 and Thr308 (Fig. 3e) . Consistent with PTEN-dependent feedback regulation, deletion of Pten caused hyperactivation of PI3K-AKT signaling and downregulation of the pre-BCR, IL-7R and CD19 (Figs. 1f-h and 3f), all of which mediate PI3K-AKT activation in pre-B cells. SYK is a B cell-specific tyrosine kinase that links pre-BCR signaling to PI3K activation [12] [13] [14] [15] . To measure the contribution of individual components of the PI3K-AKT pathway in inducing toxicity, we used selective small-molecule inhibitors of the SYK (PRT06207), PI3K (BKM120) and AKT (AZD5363) kinases (Fig. 3f) . Consistent with the toxicity induced by hyperactivation of AKT in pre-B ALL cells, pharmacological inhibition of AKT by treatment with AZD5363 greatly reduced the toxicity mediated by Pten deletion ( Fig. 3g and Supplementary Fig. 5a ). Also inhibition of SYK (using PRT06207) and PI3K (using BKM120) mitigated the toxic effects of the Pten deletion. Given that BCR-ABL1 and NRAS G12D can activate AKT independently of SYK and PI3K, treatment of cells with the AKT inhibitor AZD5363 had the strongest protective effect in reducing cell death induced by the Pten deletion ( Fig. 3h and Supplementary Fig. 5b ). npg Both alleles of Pten are required for survival and proliferation of pre-B ALL cells Deletion of PTEN in human cancer typically affects one allele, whereas the other copy is retained 25 , suggesting that cancer cells are selected for the deletion of one but not both alleles of PTEN. Indeed, deletion of both Pten alleles induces p53-dependent senescence in a model of prostate cancer, unless Trp53 is also deleted 25 . For this reason, we studied the consequences of both heterozygous and homozygous deletion of Pten in mouse pre-B ALL cells ( Supplementary Fig. 6 ). By comparing the cells in which either one (Pten +/fl ) or both (Pten fl/fl ) alleles of Pten were deleted, we found that, in contrast to solid tumor cells, both heterozygous and homozygous deletion of Pten affected colony formation and proliferation of pre-B ALL cells and induced cellular senescence. The deleterious effects of mono-and bi-allelic Pten ablation in pre-B ALL cells were indistinguishable ( Supplementary Fig. 6a-c) . Likewise, deletion of either both or only one allele of Pten compromised leukemogenesis in an in vivo transplant experiment, and no difference was noted between pre-B ALL cells carrying a deletion of one or both alleles of Pten ( Supplementary Fig. 6d ). Western blot analysis revealed that deletion of one allele of Pten resulted in increased phosphorylation of AKT ( Supplementary Fig. 6e) ; however, this increase was less than the AKT phosphorylation observed in response to the bi-allelic deletion of Pten. [4] [5] [6] . Both loss-and gain-of-function mutations of PIK3CA and PIK3R1 trigger negative selection of pre-B cells and cell death [4] [5] [6] . PI3K-AKT signaling is activated downstream of the pre-BCR and its co-receptor CD19 (refs. 4,5) . Previous work had demonstrated that tonic activation of PI3K-AKT signaling can rescue early B cell development in the absence of a functional pre-BCR 4,5 . Here we asked whether pharmacological inhibition of PI3K-AKT signaling can rescue negative selection and cell death in response to acute activation of an autoreactive pre-BCR. To test this hypothesis, we used a reconstitution system 26 for inducible activation of pre-BCR signaling downstream of non-autoreactive (µ-HC NA ) or autoreactive (µ-HC Auto ) µ-heavy chains or an empty-vector control (EV; Fig. 4a ). Tamoxifen (Tam)-induced assembly of the proximal BCR signalosome in the presence of EV or µ-HC NA had no effect on the viability of BCR-ABL1-expressing pre-B ALL cells ( Fig. 4b and Supplementary Fig. 7a ). However, inducible activation of signaling from an autoreactive pre-BCR (µ-HC Auto ) caused rapid cell death, which could be rescued by small-molecule inhibition of SYK (using PRT06207) and AKT (using AZD5363) kinase activity ( Fig. 4b and Supplementary Fig. 7a ). Activation of signaling from an autoreactive µ-HC (µ-HC Auto ) and induction of cell death involved phosphorylation of SYK and AKT, whereas activation of pre-BCR signaling downstream of µ-HC NA and EV had no effect on phosphorylation levels of SYK and AKT (Fig. 4c) . Treatment with the SYK and AKT inhibitors rescued toxicity and demonstrated that hyperactivation of SYK and AKT downstream of signaling through an autoreactive pre-BCR was required to induce cell toxicity by engaging a negative selection checkpoint (Fig. 4b) . We conclude that hyperactivation of PI3K-AKT signaling after deletion of Pten is functionally equivalent to hyperactivation of PI3K-AKT downstream of signaling through an autoreactive pre-BCR via SYK. Both events trigger a deletional checkpoint for the removal of autoreactive B cell clones.
To demonstrate the toxic effects of SYK and AKT hyperactivation in a genetic experiment, we transduced pre-B ALL cells with constitutively active (CA) forms of SYK (SYK CA ) and AKT (AKT CA ) and measured pre-B ALL cell viability in the presence or absence of the Syk, PI3K and AKT inhibitors. As predicted, SYK CA rapidly induced cell death in pre-B ALL cells, which could be almost completely rescued by inhibition of SYK, PI3K and AKT kinase activity ( Fig. 4d and  Supplementary Fig. 7b) . Likewise, hyperactivation of AKT (AKT CA ) was toxic in pre-B ALL cells, and toxicity was reduced by treatment with AKT kinase inhibitor AZD5363 (Fig. 4e and Supplementary  Fig. 7c) . Collectively, these findings suggest that hyperactivation of PI3K-AKT signaling engages a deletional checkpoint for the removal of autoreactive B cells.
B cell-specific expression and activity of PTEN To test the basic premise of a checkpoint for the elimination of autoreactive pre-B cells, we reprogrammed pre-B ALL cells into myeloid lineage cells using an inducible CCAAT-enhancer-binding npg protein alpha (C/EBP-α) vector system 27 . To this end, we engineered Pten fl/fl pre-B ALL cells with a doxycycline-inducible vector system for expression of the myeloid transcription factor C/EBP-α, which results in B→myeloid lineage conversion (Fig. 4f-h ). Inducible expression of C/EBP-α in pre-B ALL cells not only downregulated PAX5, a transcription factor that determines B cell lineage identity, but also resulted in downregulation of PTEN levels, demonstrating that PTEN expression levels depend on B cell lineage identity (Fig. 4g) . C/EBP-α-mediated myeloid lineage conversion also resulted in a 45-fold increase in phosphorylation of Ser473 in AKT, as compared to that in the EV-transduced cells, which mirrors transcriptional repression of PTEN in myeloid cells (Fig. 4g) . These findings are consistent with the notion that myeloid cells, unlike B lineage cells, are permissive to the loss of PTEN function and hyperactivation of AKT signaling. To test whether B→myeloid lineage conversion erases dependency on PTEN-mediated negative regulation of AKT activity, Pten fl/fl pre-B ALL cells carrying inducible C/EBP-α or empty-vector controls (EV) were also induced to express Cre (Fig. 4h) . Inducible deletion of Pten resulted in a rapid elimination of B cell-lineage ALL cells (CD19 + Mac1 − ) as in previous experiments (Fig. 1c-f and Supplementary Fig. 1 ). By contrast, deletion of Pten in B→myeloid-reprogrammed cells (CD19 − Mac1 + ) resulted in a slight increase in the frequency of Cre-GFP + cells, reflecting a relative survival advantage for Pten deletion in myeloid cells (Fig. 4h) . These findings are consistent with a previous study 17 that identified PTEN as a tumor suppressor in BCR-ABL1-transformed myeloid leukemia and reinforce the notion that normal pre-B and pre-B ALL cells are uniquely dependent on negative regulation of AKT by PTEN.
The deleterious effects of Pten deletion in pre-B ALL are linked to B cell lineage identity Pre-B (Ph + ALL) and CML are both driven by the oncogenic BCR-ABL1 tyrosine kinase but markedly differ with respect to PTEN expression levels (Fig. 5a,b) . PTEN protein levels were high in BCR-ABL1-driven mouse pre-B ALL cells and in patient-derived Ph + ALL cells (n = 5) but barely detectable in mouse CML-like and in patient-derived CML cells (n = 5; Fig. 5a,b) . This difference is consistent with regulation of Pten levels during B→myeloid reprogramming (Fig. 4g) . Although pre-B cells are subject to a deletional checkpoint for the removal of autoreactive clones, this is not the case for other cell types (including myeloid cells). Similarly, deletion of Pten in normal myeloid progenitor cells showed no effects but caused toxicity in normal pre-B cells (Fig. 5c) . Moreover, Cre-mediated Pten deletion had no deleterious effects in BCR-ABL1 myeloid lineage CML but caused cell death in BCR-ABL1-transformed pre-B ALL cells (Fig. 5d) . Induction of cell death after Pten deletion in pre-B ALL cells was paralleled by accumulation of the ARF, p53 and p21 cell cycle checkpoint molecules. In contrast, Pten deletion in myeloid leukemia cells induced neither activation of checkpoint molecules nor cell death 
npg
( Fig. 5d,e) . Consistent with its function as a regulator of an autoimmunity checkpoint, these findings suggest that PTEN is specifically required for the survival of normal and transformed pre-B cells and is dispensable in myeloid cells. Activation of p53 after deletion of Pten involved increased p53 phosphorylation at Ser15, which increases p53 stability and its half-life (Fig. 5f) . Notably, both Ser15-phosphorylation and accumulation of p53 were reversed by AKT inhibition (by AZD5363 treatment), indicating that activation of p53 in response to Pten deletion is caused by AKT hyperactivation (Fig. 5f) .
AKT hyperactivity exacerbates glucose and energy depletion AKT promotes glycolysis and the use of cellular ATP for translation, cell growth and proliferation through activation of mechanistic target of rapamycin complex I (mTORC1) 28, 29 . We studied the metabolic consequences of Pten deletion on glycolysis and energy supply after inhibiting mTORC1 activity by treatment with rapamycin. As expected, inducible deletion of Pten resulted in an increase in glycolysis, as measured by increased glucose consumption and increased production of lactate (Supplementary Fig. 8 ). These effects were reversed by rapamycin treatment, indicating that the increased levels of glycolysis observed after Pten deletion were caused by mTORC1 activation. Consistent with increased energy-inefficient glycolysis, inducible deletion of Pten in pre-B ALL cells reduced ATP levels, which were restored by rapamycin treatment ( Supplementary  Fig. 8 ). These metabolic effects of Pten deletion were specific for B lymphoid cells. B→myeloid reprogramming of pre-B ALL cells using inducible expression of C/EBP-α (Fig. 4f-h ) revealed that ablation of Pten had divergent outcomes in B lymphoid and B→myeloid-reprogrammed leukemia cells. Although loss of Pten moderately increased glycolysis in myeloid cells, resulting in a substantial net gain of cellular ATP levels, glycolytic activity was excessively increased in B lymphoid cells, which resulted in depletion of glucose reserves and in near-exhaustion of cellular ATP levels (Fig. 5g) . Taken together, these findings indicate that deletion of Pten in pre-B ALL cells caused profound metabolic distress in conjunction with strong activation of p53 checkpoint activation in pre-B ALL cells. It should be noted that we tested alternative mechanisms of toxicity related to Pten deletion, including dephosphorylation of signal transducer and activator of transcription 5 (STAT5) and accumulation of cellular reactive-oxygen species (ROS). Unlike metabolic stress and p53-mediated cell death, loss of STAT5 phosphorylation and increased ROS levels were only observed in BCR-ABL1-transformed ALL cells and could not be mechanistically validated in other ALL subtypes (data not shown).
Validation of PTEN as a therapeutic target in patient-derived pre-B ALL cells Despite the well-characterized function of PTEN as a tumor suppressor, to test whether PTEN represents a therapeutic target in human pre-B ALL, we used patient-derived pre-B ALL cells in which either of two distinct shRNAs specific for PTEN or a scrambled control shRNA were delivered using a lentivirus. Expression of the PTEN-specific shRNA hairpins reduced PTEN protein levels by twofold to fourfold as compared to expression of the nontargeting (scrambled) control, as determined by western blot analysis (Fig. 6a) . shRNA-mediated knockdown of PTEN in three human myeloid lineage CML cell lines did not affect cell viability, as compared to cells expressing the control shRNA ( Fig. 6b and Supplementary Fig. 9 ). In contrast, PTEN knockdown induced cell death in cells from four individuals with pre-B ALL who harbored the BCR-ABL1 (subjects LAX2 and ICN1), TCF3-PBX1 (subject ICN12) or KRAS G12V (subject LAX7R) oncogenes ( Fig. 6b and Supplementary Fig. 9 ). We conclude that PTEN is essential for the survival of human pre-B ALL cells, thus validating PTEN as a potential therapeutic target in human pre-B ALL. 
Preclinical evaluation of PTEN inhibitor in pre-B ALL treatment To test potential therapeutic usefulness of the pharmacological inhibition of PTEN, we studied the effects of a small-molecule inhibitor of PTEN, SF1670 (refs. 30,31) , in human pre-B ALL cells (Fig. 6c) . Biochemical validation of SF1670 activity revealed that treatment with this PTEN inhibitor induced activation of AKT signaling in cells from individuals with pre-B ALL who carried the BCR-ABL1 or KRAS G12V oncogenes within 1 h of treatment (Fig. 6d) . SF1670 treatment strongly and selectively induced cell death in pre-B ALL cells at similar concentrations that were previously used to stimulate neutrophils in vivo 31 (concentration required for stimulation of 50% of cells (IC 50 ) = 1.2 µmol/liter; Fig. 6e and Supplementary Fig. 10a ).
In addition, treatment with SF1670 shows a similar B cell lineagespecific effect to that observed using genetic approaches (i.e., deletion of Pten and shRNA-mediated knockdown of PTEN), as myeloid CML cells were either not affected by SF1670 treatment or affected only at higher concentrations (Fig. 6e) . In addition, treatment of human pre-B ALL cells with SF1670 phenocopied the effects of a genetic deletion of Pten fl/fl in pre-B ALL cells. Of note, the acute deletion of Pten in Pten fl/fl pre-B ALL cells resulted in phosphorylation (Ser15) and activation of p53 (Fig. 5f) . Similarly, small-molecule inhibition of PTEN resulted in rapid activation of the p53 and p21 checkpoint molecules and in p53 phosphorylation at Ser15 (Fig. 6f) . To test whether p53 checkpoint activation represents an important aspect of toxicity in pre-B ALL cells that results from acute PTEN inhibition, we transduced Trp53 fl/fl BCR-ABL1-transformed pre-B cells with a Cre-expressing or an empty-vector (EV) construct. Notably, Trp53 deletion caused a substantial shift in the dose-response curves of cells treated with SF1670. (Fig. 6g) . Although Cre-mediated deletion of Pten resulted in the rapid loss of cell surface expression of CD19 and the pre-BCR (VpreB) (Fig. 1f and Supplementary Fig. 10b) , we observed the same effects in human pre-B ALL cells that were treated for 2 d with SF1670 (Supplementary Fig. 10b ). Because prolonged systemic inhibition of PTEN would presumably raise safety concerns owing to its role as a tumor suppressor in a wide range of cell types 8, 18 , we tested the effects of short, transient inhibition of PTEN using SF1670 treatment. A single exposure to SF1670 for 3 h (and subsequent washout of SF1670) induced AKT hyperactivation and caused significant cell death in pre-B ALL cells (P < 0.001; Fig. 6h) . Small-molecule inhibition of PTEN also recapitulated metabolic features of the genetic deletion of Pten (Fig. 6i) . Although SF1670 treatment resulted in a moderate stimulation of glycolysis (glucose consumption and lactate production) in CML cells, stimulation of glycolytic responses was much stronger in B lymphoid ALL cells (Fig. 5g) . However, SF1670 treatment resulted in a net increase in cellular ATP in myeloid CML cells but a near-complete depletion of energy reserves in patient-derived pre-B ALL cells. Thus, SF1670 treatment induced pre-B cell-specific depletion of ATP and energy crisis, which recapitulated the measurements we observed in response to Cre-mediated deletion of Pten in myeloid leukemia and pre-B ALL cells (Fig. 5g) . The vast majority of newly generated pre-B cells express an autoreactive immunoglobulin µ-heavy chain, which results in strong pre-B cell receptor signaling, and are eliminated at this checkpoint 2, 3 . Humans carrying germline mutations that result in hyperactive PI3K-AKT signaling have profound B cell lymphopenia 6 , presumably because almost all newly generated pre-B cells are subject to negative selection owing to hyperactive PI3K-AKT signaling.
Recent work from our group demonstrated that central B cell tolerance checkpoints are fully functional in human pre-B ALL cells, despite their malignant transformation 32, 33 . Here we demonstrated that PTEN represents a critical gatekeeper of this checkpoint. Despite its tumor suppressor function in all major subtypes of cancer, PTEN is required to prevent indiscriminate checkpoint activation. Reflecting the unique function of PTEN in central B cell tolerance, pre-B ALL was the only subtype of human cancer that we found to be exempt from PTEN lesions (Fig. 3a) . Previous work demonstrated that pre-B cells need a minimum level of PI3K-AKT signaling to survive 5 and that targeting of this pathway is potentially useful in the treatment of human pre-B ALL 34 . However, here we propose that acute inhibition of PTEN or direct pharmacological hyperactivation of PI3K-AKT signaling may represent a strategy to trigger central B cell tolerance checkpoints and thereby overcome conventional drug resistance in human pre-B ALL.
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